Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Scott H. Davis who wrote (2600)	1/17/2001 4:35:17 PM
From: Biomaven	Respond to of 52153

Scott, short interest only thru 12/15 No, this only gets reported to the exchanges and released once a month - 12/15 is as up-to-date as there is. The WSJ site seems to get the NYSE report quickest. Peter

To: Scott H. Davis who wrote (2600)	1/17/2001 6:08:41 PM
From: Jibacoa	Respond to of 52153

The latest short interest should be out later this week, up-dated to 1/15/01. Did you see the report on the Motley Fool on Biotechs today and yesterday? : fool.com fool.com On today's report they mentioned Amgen and Celera: Amgen: Amgen has issued ambitious targets for 2005, calling for $8-9 billion in revenue, up from about $3.6 billion in the last 12 months. As for the coming quarter, the company laid out its projections pretty clearly in its third-quarter earnings. EPS should come in around $0.20. The more noteworthy part of the announcement will be the progress report on products in the pipeline, particularly ARANESP, which is expected to launch in the middle of 2001. We'll also pay attention to updates on Abarelix and SD/01, which are seeking approval from the FDA by the end of 2002. Celera Genomics: This company is not valued according to its earnings in the next few years. We'll be much more interested to hear what the company has to say about new business initiatives, particularly in the area of drug discovery. Peter Chambre, the company's chief operating officer, recently spoke at the J.P. Morgan H&Q health-care conference. He said "The next step is building a drug discovery engine to transform Celera into a drug discovery company. Implementation is now underway." We look for Celera to get into the business of drug discovery, if not drug development. We've even painted a picture of what the company might look like then. We're interested to know what CEO J. Craig Venter has to say about it in the upcoming conference call.